Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

3'-phosphoadenosine 5-phosphosulfate Synthase (PAPSS) - A Potential Therapeutic Target for Non-Small Cell Lung Cancer

FY 2011-12

Summary
Lung cancer is the top killing cancer in Canada for both men and women. Non-small cell lung cancer (NSCLC) accounts for about 80% of the cases, of which two out of three patients would have an inoperable disease at diagnosis. Inoperable NSCLC is treated with a standard combination therapy of two chemotherapy drugs, with one being typically cisplatin. Unfortunately, over 80% of the patients would still progress to a treatment-unresponsive state within three years and only 15% would survive to 5 years. Therefore, it is important to develop new treatment strategies to improve the prognosis of NSCLC. We hypothesize that certain genes in cancer cells are activated when they are first treated with anticancer drugs, triggering pathways that confer cell survival and bring about resistance mechanisms that make further treatment attempts challenging. Inhibition of these genes and gene products should enhance the effects of current first line treatments, lowering the risks of developing recurrent cancers and drug resistance. Recently, a siRNA (small-interfering RNA) screen that individually shut down or silenced each gene of the human genome identified 3'-phosphoadenosine 5'-phosphosulfate synthase (PAPSS) as a gene that, when silenced, increases cisplatin activity by over five-fold. Mutations in PAPSS could cause skeletal problems but the protein's role in cancer remains unknown. We aim to uncover PAPSS's role in cancer and assess its potential as a therapeutic target in NSCLC. Dose response to cisplatin in normal and NSCLC cells will be explored using high content screening methods and PAPSS-silencing siRNAs. A computer-led screen will also help identify existing drug candidates against PAPSS, which will then be evaluated as part of a cisplatin-containing chemotherapy cocktail against NSCLC cells. This project will increase our understanding of PAPSS in the context of NSCLC and even cancer in general, as well as the therapeutic value of its inhibition in inoperable NSCLC.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
255332
Name
Leung Ada W
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
3'-phosphoadenosine 5-phosphosulfate Synthase (PAPSS) - A Potential Therapeutic Target for Non-Small Cell Lung Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cisplatin; Combination Therapy; Gene Silencing; High Content Screening; Non-Small Cell Lung Cancer; Papss; Sirna Screen
Abstract
Lung cancer is the top killing cancer in Canada for both men and women. Non-small cell lung cancer (NSCLC) accounts for about 80% of the cases, of which two out of three patients would have an inoperable disease at diagnosis. Inoperable NSCLC is treated with a standard combination therapy of two chemotherapy drugs, with one being typically cisplatin. Unfortunately, over 80% of the patients would still progress to a treatment-unresponsive state within three years and only 15% would survive to 5 years. Therefore, it is important to develop new treatment strategies to improve the prognosis of NSCLC. We hypothesize that certain genes in cancer cells are activated when they are first treated with anticancer drugs, triggering pathways that confer cell survival and bring about resistance mechanisms that make further treatment attempts challenging. Inhibition of these genes and gene products should enhance the effects of current first line treatments, lowering the risks of developing recurrent cancers and drug resistance. Recently, a siRNA (small-interfering RNA) screen that individually shut down or silenced each gene of the human genome identified 3'-phosphoadenosine 5'-phosphosulfate synthase (PAPSS) as a gene that, when silenced, increases cisplatin activity by over five-fold. Mutations in PAPSS could cause skeletal problems but the protein's role in cancer remains unknown. We aim to uncover PAPSS's role in cancer and assess its potential as a therapeutic target in NSCLC. Dose response to cisplatin in normal and NSCLC cells will be explored using high content screening methods and PAPSS-silencing siRNAs. A computer-led screen will also help identify existing drug candidates against PAPSS, which will then be evaluated as part of a cisplatin-containing chemotherapy cocktail against NSCLC cells. This project will increase our understanding of PAPSS in the context of NSCLC and even cancer in general, as well as the therapeutic value of its inhibition in inoperable NSCLC.
Competitiondate
201202
Approvedterm2
1 yr 0 mth
Pinamesdelim
Leung, Ada W
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~